Related Experiment Video
Updated: Sep 12, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Optimizing neoadjuvant chemoimmunotherapy cycles based on radiologic response improves efficacy and survival in
Jingyu Chen1, Yichen Dong1, Juemin Yu1
1Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Background:
The optimal number of neoadjuvant chemoimmunotherapy cycles in non-small cell lung cancer (NSCLC) remains unclear. This study evaluates whether determining the number of treatment cycles based on interim radiologic response after the initial two cycles impacts therapeutic efficacy and survival.
Methods:
We retrospectively identified 395 patients with stage IIB-IIIB NSCLC who received 2-4 cycles of neoadjuvant chemoimmunotherapy between September 2020 and April 2024. Propensity score matching (PSM) was conducted between 2-cycle and 3-4-cycle groups, yielding 155 matched pairs. Patients were further stratified into partial response (PR) and stable disease (SD) subgroups based on their radiologic response after the first 2 cycles. Overall survival (OS) and recurrence-free survival (RFS) were estimated using the Kaplan-Meier method, and logistic regression was used to identify factors associated with postoperative complications.
Results:
In the overall matched cohort, receiving 3-4 cycles of neoadjuvant chemoimmunotherapy was significantly associated with improved OS (P=0.01) and RFS (P=0.03), increasing 24-month RFS rates from 72.5% to 78.2%. Such improvements were observed without an increase in the risk of postoperative complications. Subgroup analysis revealed 3-4 cycles significantly prolonged RFS in patients with SD after 2 cycles (P=0.045), improving 24-month RFS from 60.9% to 72.8%. In this subgroup, continued treatment also significantly reduced residual viable tumor (RVT) (20.0% vs. 57.5%, P=0.04) and showed a trend toward an improved major pathological response (MPR) rate (43.8% vs. 31.8%). Conversely, no additional benefits were observed in patients who achieved an early PR.
Conclusions:
For patients with radiologic SD after 2 cycles, continuing treatment to 3-4 cycles was associated with further reduction in RVT and prolonged RFS without increasing postoperative complications. By contrast, minimal benefit was observed with continued therapy in patients who achieved PR.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...